narrow-band UVB phototherapy

DEVICE2 trials

Sponsors

Brigham and Women's Hospital, Pfizer

Conditions

Active Non-segmental VitiligoOral Chronic Graft-versus-host Disease

Phase 2

UVB Phototherapy Treatment of Oral Chronic GVHD

TerminatedNCT00374257

Brigham and Women's HospitalOral Chronic Graft-versus-host Disease

Start: 2006-08-31End: 2008-09-30Updated: 2025-12-19

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

CompletedNCT03715829

PfizerActive Non-segmental Vitiligo

Start: 2018-11-26End: 2021-02-05Updated: 2022-03-25

Related Papers

Automated Measurement of Depigmentation Extent with a New AI Tool Applied to the Example of Vitiligo

Dermatology and Therapy2026-05-04

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

JEADV Clinical Practice2026-01-12

Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo

SKIN The Journal of Cutaneous Medicine2025-11-10

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Vitiligo

Epidemiologia e Serviços de Saúde2025-01-01

Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo

Archives of Dermatological Research2024-07-189 citations

Current best evidence in pigmentary dermatology

Pigment International2024-05-01

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

Clinical Pharmacokinetics2023-11-0215 citations

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.

2023-09-2821 citations

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, dose-ranging study with an extension period

British Journal of Dermatology2023-01-18

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.

2022-11-0971 citations